Drug intelligence / Profile preview

NEPHRIL

Development stage: Preclinical
Lead developer: Panion & BF Biotech
Administration: Oral

Overview

NEPHRIL is an early-stage drug candidate currently in the research and development pipeline of Panion & BF Laboratories. It is categorized by the developer as a 'New Drug' within their technological platform. While specific details regarding its molecular target, mechanism of action, and primary therapeutic indications have not been publicly disclosed, the name 'NEPHRIL' and the developer's existing product portfolio (which includes the phosphate binder Nephoxil) suggest a potential focus on nephrology or renal-related metabolic disorders. The candidate is currently considered to be in the preclinical stage of development.

Other names: Nephril-Panion BF Laboratories

Beyond the preview

Go deeper on NEPHRIL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NEPHRIL.

Explore the full profile